ClinicalTrials.gg
RecruitingNCT05741593QUATROUpdated Nov 18, 2024

Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated with Antithrombotics for an Ischemic Stroke.

An observational study in Stroke, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Ages
65 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Stroke by Hospices Civils de Lyon — 13 open to participants now, 14 under way, none of them phase 3. Stroke · Hospices Civils de Lyon.

Planned enrollment
13th of 14
30 · median 348
Started
2025
with 3 others
Observational
14 of 40
5 open now
Primary completion
2026-04
later than 2 of 13 live
Registered
30th of 40
by date

Among the 40 studies in Stroke by Hospices Civils de Lyon, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 30th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

13 of the 40 studies in Stroke by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 65 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Stroke by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.

Read the detailed description

Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. The probability of stroke recurrence is high: about 25% the first year , and 30 to 40% in the 5 years following the stroke. Recurrent strokes are responsible for significant disability, institutionalization, major neurocognitive disorders, and death.

In order to reduce the risk of stroke recurrence, multiple secondary prevention strategies have demonstrated their effectiveness, such as the prescription of drugs (in particular statins and antithrombotics), the establishment of a balanced diet, the practice of an activity physical, or even tobacco addiction.

However, the effectiveness of these strategies is optimal if and only if patients adhere to them.

In addition, previous studies have focused on the brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.

In elderly patients, other obstacles could have been identified by specific studies, such as cognitive, sensory, functional disorders or even isolation.

03

Conditions studied

  • Stroke

Keywords

  • Qualitative study
  • semi-structured interview
  • antithrombotic
  • stroke
  • medication adherence
04

Who can participate

Ages eligible
65 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 65 and over, hospitalized for an ischemic stroke or a recurrence of ischemic stroke, being already treated with an antithrombotic treatment hospitalized at the Charpennes hospital with a plan to return home

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 65 and over
  • Patients hospitalized for an ischemic stroke or a recurrence of ischemic stroke, already being treated with an antithrombotic treatment (antiplatelet agent or anticoagulant ) prior to the stroke
  • Patients living at home and with a plan to return home.
  • Patients who did not object to the study and who gave their consent for the recording of the interview

Exclusion criteria

Exclusion Criteria:

  • Patients with cognitive disorders or stroke sequelae that do not allow a semi-directive interview to be carried out (at medical discretion).
  • Non-French speaking patients
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients having had a stroke

    elderly patients previously treated with an antithrombotic and admitted to hospital for an ischemic stroke

    Other: Analysis of the verbatim from the transcription of the recorded interviews.

Interventions

  • OtherAnalysis of the verbatim from the transcription of the recorded interviews.

    recorded semi-structured interviews between the patients and the pharmacist

06

What researchers measure

Primary outcomes

  1. Analysis of the verbatim from the transcription of the recorded interviews.

    Describing the content of discussions, relating to antithrombotic treatment for secondary prevention, between elderly patients previously treated with antithrombotics and admitted to hospital for an ischemic stroke and a pharmacist

    Time frame: one year

Secondary outcomes

  1. Analysis of verbatim statements from the transcription of recorded interviews on patients' representations and beliefs regarding antithrombotics

    Exploring patients' representations and beliefs regarding antithrombotics before and after the onset of stroke or recurrence of stroke

    Time frame: 15 to 60 minutes per patient

  2. Analysis of verbatim statements from the transcription of recorded interviews on patients' medication adherence to antithrombotics

    Explore patients' medication adherence to antithrombotics before the onset of stroke or recurrence of stroke

    Time frame: 15 to 60 minutes per patient

  3. Analysis of verbatim statements from the transcription of recorded interviews on the impact of the occurrence of stroke or recurrence of stroke on medication adherence

    Explore the impact of stroke occurrence or stroke recurrence on patient medication adherence (including motivation, ambivalence, confidence in medication benefits)

    Time frame: 15 to 60 minutes per patient

  4. Analysis of verbatim statements from the transcription of recorded interviews on the obstacles and levers to medication adherence

    Identify the barriers and levers to drug adherence with antithrombotics

    Time frame: 15 to 60 minutes per patient

07

Study locations

1 of 1 sites recruiting
  • institute of aging - Hôpital des Charpennes
    Villeurbanne, 69100, France
    Recruiting
    • Teddy NOVAIS, PharmD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Apr 2026, 12 months later.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 12 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 23, 2023
StartEst.
Apr 1, 2025
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05741593
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
Apr 1, 2025 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Nov 18, 2024

Study contacts

Teddy Novais, PharmD, PhD
Contact
teddy.novais@chu-lyon.fr
+33472432155

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion